We are BioSynaptica, a biotechnology startup dedicated to the development of innovative biopharmaceuticals for the treatment of neurodegenerative diseases. Currently, there are no effective treatments that can prevent or cure these conditions. Therefore, through our technology, we aim to halt their progression and improve people’s quality of life.

At BioSynaptica, we believe in science as a central discipline for improving people’s quality of life.

Our development focuses on creating an innovative neuropharmaceutical derived from human erythropoietin (hEPO) to meet the needs of individuals suffering from nervous system disorders such as Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, neurotraumas, degenerative retinopathies, among others.

hEPO is a biotherapeutic used for the treatment of certain types of anemia, as it produces and maintains red blood cells in circulation. Additionally, hEPO exhibits neuroprotective and neuroplastic activity. However, when used as a neuropharmaceutical in anemia-non suffering patients, it causes side effects associated with its erythropoietic action.

Our team achieved a significant milestone: modifying the hEPO molecule to eliminate its undesirable effect while preserving its neuroprotective and neuroplastic capabilities, which have been demonstrated in vivo using healthy animals and an animal model of degenerative retinopathy. This important breakthrough improves the properties of hEPO to use in the treatment of chronic degenerative diseases.